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  Abstract 
    Introduction  . Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is 
a rapidly acting (  t    ½    ∼  1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue 
esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efﬁ  cacy of cle-
vidipine in patients with RD.   Methods  . VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 
patients with persistent systolic blood pressure (SBP)     180 mmHg. Investigators pre-speciﬁ  ed a SBP initial target range 
(ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via 
peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 min as needed to a maximum of 32 mg/h (non-weight-
based treat-to-target protocol). Per protocol, clevidipine was continued for at least 18 h (96 h maximum). RD was diagnosed 
and reported as an end-organ injury by the investigator and was deﬁ  ned as requiring dialysis or an initial creatinine     2.0 
mg/dl. Primary endpoints were the percentage of patients within the ITR by 30 min and the percentage below the ITR 
after 3 min of clevidipine infusion.   Results  . Of the 24 patients with moderate to severe RD, most (13/24) were dialysis 
dependent. Forty-six percent were male, with mean age 51    14 years; 63% were black and 96% had a hypertension history. 
Median time to achieve the ITR was 8.5 min. Almost 90% of patients reached the ITR in 30 min without evidence of 
overshoot and were maintained on clevidipine through 18 h. Most patients (88%) transitioned to oral antihypertensive 
therapy within 6 h of clevidipine termination.   Conclusions  . This report is the ﬁ  rst demonstrating that clevidipine is safe and 
effective in RD complicated by severe hypertension. Prolonged infusion maintained blood pressure within a target range 
and allowed successful transition to oral therapy.   
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  Introduction 
  Approximately 72 million people in the USA suffer 
hypertension and it is estimated that 1  –  2% of patients 
with hypertension will at some point develop a hyper-
tensive crisis. The Seventh Report of the Joint National 
Committee on Detection, Evaluation, and Treatment 
of High Blood Pressure (JNC7) identiﬁ  es patients 
with a systolic blood pressure (SBP)     180 mmHg 
or a diastolic blood pressure (DBP)     120 mmHg 
as having a   “  hypertensive crisis  ”   (1). Hypertensive 
crisis is further deﬁ  ned as   “  hypertensive emergen-
cies  ”   (i.e. severe elevations with evidence of impend-
ing or progressive end-organ dysfunction such as 
renal dysfunction, RD) that requires immediate 
blood pressure (BP) reduction to prevent or limit 
end-organ damage, or   “  hypertensive urgencies  ”   
(i.e. severe elevations in BP without end-organ dys-
function). Patients with   “  severe  ”   or   “  accelerated  ”   hyper-
tension (i.e. an SBP    179 mmHg or a DBP    109 
mmHg and have a recent signiﬁ  cant increase in BP 
with evidence of target organ damage) should also 
be treated as hypertensive crisis patients. 
  The pathophysiology of acute severe hyperten-
sion, although not completely understood, is thought 
to be related to abrupt increases in systemic vascular 
resistance related to humoral vasoconstrictors and 
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can develop   de novo,   or can complicate already exist-
ing essential hypertension. The goal of intervention 
in a hypertensive crisis is to reduce BP safely. The 
appropriate therapeutic approach to each patient will 
depend on their clinical presentation. 
  The optimal treatment options of each patient 
type, especially those with RD, have yet to be clearly 
elucidated. Since diuretics are less effective in 
patients with RD, vasodilators are commonly used 
for acute BP control. Limited clinical data are avail-
able to help guide physicians as to which vasodilator 
is most safe and effective in the setting of RD. As 
these patients often present with numerous comor-
bidities, and their acuity may be exacerbated by 
severe hypertension, many intravenous (IV) antihy-
pertensives are either contraindicated or challenging 
to use in the patient with RD. The ideal treatment 
modality remains to be determined; nonetheless, 
some recommendations on the management of 
severely hypertensive patients with RD, largely based 
on clinical experience, have been made and suggest 
dihydropyridine calcium-channel blockers may be 
appropriate ﬁ  rst-line agents (2). Clevidipine is the 
latest-generation dihydropyridine calcium-channel 
blocker with characteristics of arterial selectivity, 
rapid onset and offset of action, and high clearance 
(3  –  6). Clevidipine reduces BP by exerting an arterial-
speciﬁ   c, vascular-selective vasodilating effect with 
no associated negative inotropic effects (7  –  9). Unlike 
other drugs of the dihydropyridine family, such as 
nifedipine, a key characteristic of clevidipine is its 
arterial selectivity. In hemodynamic studies, clevid-
ipine has been shown to increase both stroke volume 
and cardiac output with minimal effect on heart rate 
(9). Clevidipine is an afterload reducer and does not 
affect central venous pressure. Clevidipine has an 
approximate half-life of 1 min and is metabolized by 
blood and tissue esterases independent of renal and 
hepatic function. Steady state is rapidly achieved 
with a small volume of distribution (7). It has been 
shown to achieve target BP within 5  –  6 min in over 
90% of cardiac surgery patients (3,10). In animal 
models, clevidipine has been also shown to protect 
against ischemia/reperfusion injury of myocardial 
ischemia and to maintain renal function and splanch-
nic blood ﬂ  ow (11  –  13). Moreover, in head-to-head 
clinical trials, it was found to offer improved BP 
control compared with nitroglycerin, sodium nitro-
prusside (SNP) at pre-speciﬁ   ed BP target ranges 
and nicardipine at narrower BP target ranges during 
major surgery (14). 
  With a renally independent metabolic pathway 
that generates no toxic metabolites, clevidipine may 
be useful for patients presenting with severely ele-
vated BP with concomitant RD. This subgroup anal-
ysis of the VELOCITY trial (15) was performed to 
assess safety and efﬁ  cacy of clevidipine for the treat-
ment of severe hypertension in patients presenting 
with RD.     
  Methods 
  The eValuation of the Effect of uLtra-shOrt-acting 
Clevidipine In the Treatment of patients with severe 
hYpertension (VELOCITY) trial (15) was an open-
label, single-arm study of clevidipine in patients 
aged     18 years presenting to the emergency depart-
ment or intensive care unit with severe hypertension, 
deﬁ  ned as SBP   180 mmHg and/or DBP   115 mmHg 
(assessed twice at least 15 min apart at baseline). All 
BP monitoring was done by cuff sphygmomanome-
try. The diagnosis of RD was determined by the phy-
sician after the review of all available clinical and 
laboratory data. RD was reported as an end-organ 
injury deﬁ  ned as being dialysis dependent or having 
an initial creatinine     2.0 mg/dl (baseline creatinine 
clearance     50 ml/min, derived from serum creati-
nine by the Cockcroft  –  Gault equation: 
  Men: creatinine clearance      [(140    age)      weight]/
(72      serum creatinine); 
  Women: creatinine clearance      [(140    age)      weight]/
(72      serum creatinine) 
     0.85). 
  The primary endpoints of the study were the per-
centage of patients within the initial target range 
(ITR), set by the treating physician for each indi-
vidual patient, at 30 min (efﬁ  cacy), and the percent-
age of patients below the ITR after 3 min of starting 
clevidipine infusion (safety). Times to achieving the 
ITR, mean decrease in SBP at 18 h, and incidence 
of adverse events (AEs) related to clevidipine were 
assessed as well. 
  Clevidipine (0.5 mg/ml in a 20% lipid emulsion 
vehicle) was administered by IV infusion. Using a 
non-weight-based, treat-to-target protocol, clevid-
ipine was initiated at a dosage of 2 mg/h and titrated 
as needed in doubling increments every 3 min to a 
maximum of 32 mg/h, during 30 min, and then con-
tinued for a total duration of     18 h to     96 h. If ITR 
was achieved during the ﬁ  rst 30 min, clevidipine was 
maintained at that dose to keep SBP within the ITR, 
or titrated as needed to keep SBP within the ITR. 
After the ﬁ  rst 30 min, the SBP target range could be 
altered at the discretion of the attending physician 
and additional dose adjustments made to achieve the 
new BP target. If ITR was not achieved, alternative 
IV antihypertensive agents were permitted with or 
without stopping clevidipine. 
  The VELOCITY trial was conducted in compli-
ance with the International Conference on Harmon-
isation Good Clinical Practice guidelines and the 
Declaration of Helsinki. The study was approved by 
the institutional review board at each participating 
institution. The VELOCITY trial was performed 
under IND 65,114 and was registered at clinicaltri-
als.gov under the identiﬁ  er NCT00369837. Written 
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enrollment. The VELOCITY trial was a randomized, 
open-label, prospective, single-arm study conducted 
at 14 medical centers in the USA between August 
2006 and February 2007.     
  Results 
  One hundred and twenty-six patients in the VELOC-
ITY trial received clevidipine infusion (i.e. the safety 
population), and of these, 24 (19%) had RD and 
13 (54% of all RD) were dialysis dependent. Patients 
with RD were severely hypertensive with a median 
baseline SBP of 210 and DBP of 120 mmHg. 
The median upper ITR was 180 mmHg therefore 
requiring an approximate 15% reduction from base-
line BP in the ﬁ  rst 30 min to achieve the primary 
efﬁ  cacy endpoint. There were no signiﬁ  cant differ-
ences between non-dialysis-dependent and dialysis-
dependent patients. Baseline characteristics, medical 
history and pre-speciﬁ  ed ITR of patients with RD in 
the safety population are described in Table I. 
  Similarly, of the 117 VELOCITY patients with 
SBP above their pre-speciﬁ  ed target range at clevi-
dipine initiation (modiﬁ   ed intent-to-treat popula-
tion), 22 (18.8%) had RD, of whom 12 (54.5%) 
were dialysis dependent, most were diabetic and 
over a third had a history of cardiac disease. During 
the initial 30 min of clevidipine infusion, the overall 
median infusion rate was 6 mg/h and the overall 
maximum median infusion rate was 12 mg/h. Twenty-
one of the 22 (95.5%) received clevidipine infusion 
for at least 18 h. BP response to clevidipine initiation 
was similar between the RD population and the 
non-RD cohort (Figure 1). Also similar to the over-
all patient cohort, approximately 90% of patients 
with RD (regardless of dialysis dependency) achieved 
the pre-speciﬁ  ed SBP ITR within 30 min. During 
clevidipine infusion, mean SBP decreased 7.0 mmHg 
(3.5%) at 3 min and 54.0 mmHg (25.6%) at 30 min 
(Table II). SBP was reduced steadily during the ﬁ  rst 
30 min regardless of the RD status. No patients with 
RD had SBP below ITR within 3 min of initiating 
clevidipine infusion. 
  At 18 h of clevidipine infusion, the median infu-
sion rate for patients with RD was 11 mg/h with a 
range of 1  –  32 mg/h. The mean decrease in SBP from 
baseline was 53.8 mmHg (25.3%). Clevidipine infu-
sion was maintained for 18 h without incident and 
maintained SBP to target levels. In the safety popula-
tion, 21 of 24 (87.5%) patients successfully transi-
tioned to oral antihypertensive therapy within 6 h of 
clevidipine cessation; one patient discontinued clevi-
dipine without needing transition to oral agents and 
two patients with a protocol deviation discontinued 
clevidipine after   	  18 h. 
  There was a modest 14% increase in heart rate, 
representative of a typical physiological response to 
rapid BP reduction, and no patient required cessa-
tion of clevidipine as a consequence. In the safety 
population, 12/24 patients with RD had at least one 
AE, with most being assessed by investigators as 
unrelated to clevidipine. Headache, pain in extremity 
and hypokalemia each occurred in two patients. Two 
patients (8.3%) had AEs assessed by investigators as 
related to clevidipine; one patient had increased BP 
after clevidipine infusion had been stopped and one 
patient had hyperlipidemia and renal insufﬁ  ciency. 
Two patients had AEs leading to discontinuation of 
clevidipine infusion, one for hypotension and one for 
increased triglyceride levels. Upon further examina-
tion of these patients, the hypotension was recorded 
after administration of an oral antihypertensive agent, 
where clevidipine infusion was stopped just prior to 
the 18 h and was assessed as unrelated to clevidipine 
    Table I. Baseline characteristics, medical history and pre-speciﬁ  ed initial target range (safety population patients with renal dysfunction).   
Statistic
All RD patients, 
  n        24
Non  –  dialysis-dependent 
patients,  a    n        10
Dialysis-dependent 
patients,   n        13
Age, years, mean (SD) 51.3 (14.3) 49.2 (16.5) 51.8 (12.7)
Female,   n   (%) 13 (54.2) 5 (50.0) 8 (61.5)
Weight, kg, mean (SD) 83.1 (37.6) 99.9 (48.6) 67.8 (19.5)
BMI, kg/m  2  , mean (SD) 29.4 (10.7) 33.4 (13.8) 25.4 (5.8)
African American,   n   (%) 15 (62.5) 7 (70.0) 8 (61.5)
Hispanic,   n   (%) 5 (20.8) 0 (0.0) 5 (38.5)
White,   n   (%) 3 (12.5) 2 (20.0) 0 (0.0)
Asian,   n   (%) 1 (4.2) 1 (10.0) 0 (0.0)
SBP (mmHg), median (range) 209.5 (167  –  243) 210.5 (183  –  241) 209.0 (167  –  243)
DBP (mmHg), median (range) 119.5 (72  –  148) 124.5 (77  –  140) 119.0 (84  –  148)
ITR (high, low), median (range) 180.0 (150  –  220) 182.5 (160  –  210) 180.0 (150  –  220)
150.0 (120  –  180) 160.0 (120  –  180) 140.0 (120  –  180)
MI,   n   (%) 3 (12.5) 1 (0.1) 2 (15.4)
CAD,   n   (%) 9 (37.5) 3 (30.0) 5 (38.5)
CHF,   n   (%) 9 (37.5) 2 (20.0) 7 (53.8)
Diabetes,   n   (%) 13 (54.2) 8 (80.0) 4 (30.8)
        a  Dialysis status of 1 patient is unknown. RD, renal dysfunction; SD, standard deviation; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; ITR, initial target range; MI, myocardial infarction; CAD, coronary artery disease; CHF, 
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infusion. Increased triglyceride levels in the second 
patient were confounded as the blood sample was 
taken from the same catheter as the IV infusion of 
clevidipine. The catheter was not ﬂ  ushed and these 
laboratory results were likely related to cross con-
tamination with the lipid emulsion. Serious AEs were 
recorded for two patients and were assessed as 
unlikely related and unrelated to clevidipine.     
  Discussion 
  In this subset analysis of the VELOCITY trial, clevi-
dipine rapidly and effectively lowered BP, was not 
associated with excessive or precipitous drops in BP 
and had similar results in patients with or without RD. 
This is the ﬁ  rst report to demonstrate the effects of 
clevidipine in severely hypertensive patients with mod-
erate to severe RD, with or without dialysis (16,17). 
Targeted BP control was rapidly achieved in 8.5 min 
and was maintained for the speciﬁ  ed 18 h duration 
after which most patients effectively transitioned to 
oral therapy. Patients were administered clevidipine 
using a non-weight-based treat-to-target infusion pro-
tocol and were monitored by BP cuff. Typical infusion 
rates to maintain BP control were 6  –  12 mg/h, repre-
senting a ﬂ  uid infusion volume of 12  –  24 ml/h. 
  The management of the patient with RD, espe-
cially those requiring dialysis, with associated acute 
severe hypertension can be challenging. These 
patients typically have long-standing chronic hyper-
tension, ﬂ   uid overload, underlying comorbidities 
including cardiac disease and diabetes, and resis-
tance to antihypertensive therapy often requiring 
multiple agents to achieve the desired therapeutic 
response. Moreover, because of the complicated and 
compromised nature of the patient  ’  s renal status, 
many therapies to control these hypertensive epi-
sodes are not suitable because of the potential for 
serious or fatal AEs. This is especially the case with 
the commonly used IV agent SNP. One molecule of 
SNP contains 44% cyanide by weight and is released 
non-enzymatically upon infusion. Cyanide is metab-
olized in the liver to the less toxic thiocyanate 
(18,19), which is then excreted largely through the 
kidneys. Cyanide removal, therefore, requires ade-
quate liver and renal function. Considering the 
potential for severe toxicity with SNP, this drug 
should not be used in patients with evidence of com-
promised renal function (20). Clevidipine is rapidly 
metabolized by blood and tissue esterases, allowing 
for metabolism that is independent of the kidney 
and making it a safe alternative to SNP. In this study, 
the majority of patients with RD (87.5%) were able 
to be treated with clevidipine monotherapy alone, 
while only 8.3% of clevidipine-treated patients with 
RD required treatment with more than 1 IV antihy-
pertensive agent (Table III). Likewise, 84.3% of 
patients without RD were able to be treated with 
clevidipine monotherapy alone, while only 8.7% 
required treatment with more than 1 IV antihyper-
tensive agent (Table III). 
  In this high-risk subpopulation, most AEs were 
assessed as unrelated to clevidipine treatment. This 
supports the relative safety of this product. The 
results of this subgroup analysis in patients with RD 
are also consistent with the primary results of the 
overall VELOCITY trial (15). Similarly, in other 
    Figure 1.         Mean percentage change in systolic blood pressure over 
time during clevidipine infusion for VELOCITY patients with and 
without renal dysfunction, showing similar decrease for both 
groups (modiﬁ  ed intent-to-treat population).   






  n        117   n        95   n        22
Time to ﬁ  rst reaching SBP ITR after CLV initiation, min; median (95% CI) 10.9 (9.0  –  15.0) 11.1 (9  –  15) 8.5 (7  –  17)
Patients who reached their ITR within 30 min of CLV initiation,   n   (%) 104 (88.9) 85 ( 89.5) 19 (86.4)
  n        112   n        91   n        21
Patients who reached their SBP ITR within 30 min of CLV initiation 
(excluding patients with ITR protocol deviations  a  ),   n   (%)
101 (90.2) 82 (90.1) 19 (90.5)
  n        110   n        89   n        21
Mean decrease in SBP at 3 min of CLV infusion, mmHg; mean (%) 11.8 (5.9) 12.9 (6.4) 7.0 (3.5)
  n        48   n        40   n        8
Mean decrease in SBP at 30 min of CLV infusion, mmHg; mean (%) 44.8 (21.1) 42.9 (20.2) 54.0 (25.6)
        a  ITR protocol deviation, ITR that was pre-speciﬁ  ed to be too narrow (  	  20 mmHg) or too wide (    40 mmHg) per protocol. RD, renal 
dysfunction; SBP, systolic blood pressure; ITR, initial target range; CLV, clevidipine; 95% CI, 95% conﬁ  dence interval.     24     W. F. Peacock IV et al.     
studies, clevidipine has been shown to be a safe and 
tolerable drug with almost no reported adverse 
effects in Phase III trials with a combined enroll-
ment exceeding 1800 patients. The cardiac surgery 
ESCAPE-1 and ESCAPE-2 trials demonstrated 
that the most notable adverse effect from clevid-
ipine was an increase in heart rate, which was rela-
tively small and of minimal clinical signiﬁ  cance 
(3,10). In ECLIPSE, another cardiac surgery trial, 
there were no differences in death or adverse out-
comes at the time of hospital discharge or Day 7 
among any of the treatment groups (clevidipine, 
nitroglycerine, SNP and nicardipine) (14). Finally, 
the VELOCITY trial reported no drug-related seri-
ous AEs and no episodes of rebound hypertension 
in patients with acute and severe hypertension (15). 
Clevidipine has been shown to be a safe and effective 
treatment across all pivotal studies for patients with 
acute and severe hypertension and those requiring 
pre-, intra- and post-operative management of BP 
(3,10,14,15).   
  Limitations 
  VELOCITY was an open-label, multicenter, uncon-
trolled study designed to demonstrate the safety and 
efﬁ   cacy of clevidipine. Concomitant IV antihyper-
tensive therapy was allowed at any time if needed for 
safety or lack of efﬁ  cacy; hence, each patient essen-
tially served as their own control. The deﬁ  nition for 
severe hypertension used in this study (SBP    180 
mmHg and/or DBP    115 mmHg) was developed 
according to clinical experience, as there is no uni-
versally accepted deﬁ  nition for severe hypertension 
(21,22). While the results of this subgroup analysis 
suggest that clevidipine is safe, well tolerated, and 
efﬁ  cacious for patients with RD, the relatively small 
number of patients and lack of control prevents 
broad-based conclusions from being drawn. Addi-
tional prospective studies and a larger clinical experi-
ence will be required to substantiate the safety and 
efﬁ  cacy of clevidipine further in patients with com-
promised renal function.       
  Conclusions 
  The results of this subgroup analysis of the VELOC-
ITY trial suggest that clevidipine is well tolerated and 
effective in the treatment of patients with acute severe 
hypertension with compromised renal function.     
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